Posted by Michael Wonder on 02 Aug 2024
Adverum Biotechnologies announces FDA regenerative medicine advanced therapy designation granted for ixo-vec for the treatment of wet AMD
1 August 2024 - Adverum Biotechnologies today announced that the US FDA has granted regenerative medicine advanced therapy designation for Ixo-vec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.
Ixo-vec utilises a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette.
